Adma pulls long term outlook

 

Adma Biologics misses Q1 EPS and revenue estimates with non-GAAP EPS $0.19 (+40% YoY), revenue $114.5M, maintains 2026 guidance, withdraws long-term outlook

• Q1 2026 revenue was $114.5 million, essentially flat year-over-year, while adjusted net income grew 22% year-over-year.
• Q1 net income totaled $45.3 million, or $0.19 per share, according to the company.
• Company maintained FY 2026 revenue guidance at $530–$560 million but withdrew its long-term outlook amid increasing competition in the IG market.
• Company said an internal audit found no evidence of alleged channel stuffing or undisclosed related-party transactions.

https://finviz.com/quote?t=ADMA&p=d